Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER‐ALZ 3
Alzheimer's & Dementia · 2025-09 · 21 (9)
DOI: 10.1002/alz.70662 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Alzheimer's & Dementia, online erschienen am 16.09.2025. Verfasst von Roy Yaari und 10 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Antibodies, Monoclonal, Humanized, tau Proteins. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Eli Lilly and Company.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION TRAILBLAZER‐ALZ 3 is investigating donanemab in preclinical Alzheimer's disease (AD). METHODS This double‐blind, placebo‐controlled trial used a plasma phosphorylated tau‐217 (p‐tau217) assay to detect AD pathology for eligibility and a decentralized design to enhance screening and enrollment. After nine monthly infusions, clinical assessments continue every 6 months with a time‐to‐event primary outcome. A sub‐study will evaluate longitudinal changes in amyloid and tau positron emission tomography (PET). RESULTS Participants 55–80 years of age were screened ( N = 63,124). Plasma p‐tau217‐eligible participants were enrolled ( N = 2196), with Clinical Dementia Rating (CDR) scale‐Global score (CDR‐GS) of 0 ( n = 1202) and 0.5 ( n = 664). Plasma p‐tau217 eligibility increased with age, differing across races and ethnicities. Mean baseline amyloid levels were 63.2 (CDR‐GS: 0) and 70.7 Centiloids (CDR‐GS: 0.5). Elevated global tau signal (standardized uptake value ratio ≥1.10) was observed in 15.1% and 26.3% of CDR‐GS 0 and 0.5 subgroups, respectively. DISCUSSION Utilizing a unique decentralized design, the trial showed baseline data consistent with preclinical AD. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT05026866, TRAILBLAZER‐ALZ 3 Highlights TRAILBLAZER‐ALZ 3 screened 63,124 participants in the United States and Japan Plasma phosphorylated tau‐217 (p‐tau217) was used to determine Alzheimer's disease pathology for eligibility A decentralized model was used, including remote raters for clinical testing Randomized participants had Clinical Dementia Rating scale–Global scores of 0 and 0.5
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eli Lilly and Company, Indianapolis, Indiana, USA.
- Banner Alzheimer's Institute, Phoenix, Arizona, USA.
ORCID-Profile: Roy Yaari
Förderung
- NIA NIH HHS
- Eli Lilly and Company
Zitieren
APA
Yaari, R., Holdridge, K. C., Williamson, M., Wessels, A. M., Shcherbinin, S., Kotari, V., Reiman, E. M., Tariot, P. N., Alexander, R., Langbaum, J. B., & Sims, J. R. (2025). Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER‐ALZ 3. Alzheimer's & Dementia, 21(9). https://doi.org/10.1002/alz.70662
Vancouver
Yaari R, Holdridge KC, Williamson M, Wessels AM, Shcherbinin S, Kotari V, et al. Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER‐ALZ 3. Alzheimer's & Dementia. 2025;21(9). doi:10.1002/alz.70662
BibTeX
@article{Yaari2025,
author = {Yaari, Roy and Holdridge, Karen C and Williamson, Melissa and Wessels, Alette M and Shcherbinin, Sergey and Kotari, Vikas and Reiman, Eric M and Tariot, Pierre N and Alexander, Robert and Langbaum, Jessica B and Sims, John R},
title = {Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER‐ALZ 3},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {9},
doi = {10.1002/alz.70662}
}
EUVIMED